BioVitrum plans to establish a scientific and industrial complex in Tashkent

Russian and Chinese companies have presented their projects within the framework of the Tashkent Pharma Park pharmaceutical cluster, according to the press service of the Pharmaceutical Industry Development Agency.

The agency’s director, Abdulla Azizov, held talks with a delegation from the Russian company BioVitrum, which specializes in diagnostics and laboratory services. The discussions focused on investment opportunities, benefits, and preferences available to cluster participants.

The guests shared their plans to open a research center, a quality control laboratory, and a manufacturing and storage facility in Uzbekistan. BioVitrum established a similar complex in Volkhovka, Leningrad Region, in 2024.

The Russian side also announced plans to begin production of paraffin-based products, emphasizing that “only five companies worldwide manufacture such products.”

Additionally, Azizov met with representatives of China’s Walvax Biotechnology, a company specializing in the production of high-quality vaccines. The two parties discussed the organization of joint vaccine manufacturing in Uzbekistan.

The company’s experience in technology transfer is expected to contribute to the development and uninterrupted operation of local vaccine production. In addition to domestic supply under the National Program, there is also potential to provide vaccines to Central Asian and CIS countries.